L G Moise1, D S Marta2, A Raşcu1,3, E Moldoveanu4. 1. "Carol Davila" University of Medicine and Pharmacy - Occupational Medicine Department, Bucharest, Romania. 2. "Victor Babes" National Institute of Pathology - Ultrastructural Pathology Department, Bucharest, Romania. 3. Colentina Clinical Hospital - Occupational Medicine Department, Bucharest, Romania. 4. "Titu Maiorescu" University - Faculty of Medicine, Bucharest, Romania.
Abstract
CONTEXT: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker for cardiovascular diseases (CVD) risk estimation with high specificity for vascular inflammation. Few studies have investigated Lp-PLA2 levels in patients with metabolic syndrome (MetS) and obstructive sleep apnea syndrome (OSAS). OBJECTIVE: This study aimed to evaluate the role of Lp-PLA2 levels as a marker of vascular inflammation that contributes to cardiometabolic dysfunction in patients with MetS and OSAS. DESIGN: This is a prospective case-control study. SUBJECTS AND METHODS: 83 men were enrolled. Following anthropometric measurements, laboratory analysis and overnight sleep study, patients were divided into three groups: MetS, OSAS with/without MetS. Serum Lp-PLA2 levels were determined by ELISA method. RESULTS: Serum Lp-PLA2 levels were statistically significant among the three groups and were higher in OSAS with MetS group than those without MetS. A significant positive relationship between increased Lp-PLA2 level and CRP (C-reactive protein) and apnea-hypopnea index (AHI) was found. Average oxygen saturation (AvO2) and the lowest oxygen saturation were negatively correlated with Lp-PLA2. The number of desaturation events, oxygen desaturation index, AvO2, AHI and CRP were significant predictors of Lp-PLA2. CONCLUSIONS: Lp-PLA2 levels are associated with OSAS severity and might play an important role in predicting CVD in OSAS with/without MetS.
CONTEXT: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker for cardiovascular diseases (CVD) risk estimation with high specificity for vascular inflammation. Few studies have investigated Lp-PLA2 levels in patients with metabolic syndrome (MetS) and obstructive sleep apnea syndrome (OSAS). OBJECTIVE: This study aimed to evaluate the role of Lp-PLA2 levels as a marker of vascular inflammation that contributes to cardiometabolic dysfunction in patients with MetS and OSAS. DESIGN: This is a prospective case-control study. SUBJECTS AND METHODS: 83 men were enrolled. Following anthropometric measurements, laboratory analysis and overnight sleep study, patients were divided into three groups: MetS, OSAS with/without MetS. Serum Lp-PLA2 levels were determined by ELISA method. RESULTS: Serum Lp-PLA2 levels were statistically significant among the three groups and were higher in OSAS with MetS group than those without MetS. A significant positive relationship between increased Lp-PLA2 level and CRP (C-reactive protein) and apnea-hypopnea index (AHI) was found. Average oxygen saturation (AvO2) and the lowest oxygen saturation were negatively correlated with Lp-PLA2. The number of desaturation events, oxygen desaturation index, AvO2, AHI and CRP were significant predictors of Lp-PLA2. CONCLUSIONS: Lp-PLA2 levels are associated with OSAS severity and might play an important role in predicting CVD in OSAS with/without MetS.
Authors: E Shahar; C W Whitney; S Redline; E T Lee; A B Newman; F J Nieto; G T O'Connor; L L Boland; J E Schwartz; J M Samet Journal: Am J Respir Crit Care Med Date: 2001-01 Impact factor: 21.405
Authors: Carlos Iribarren; Myron D Gross; Jeanne A Darbinian; David R Jacobs; Stephen Sidney; Catherine M Loria Journal: Arterioscler Thromb Vasc Biol Date: 2004-10-21 Impact factor: 8.311
Authors: M Serban; Cristina Tanaseanu; T Kosaka; Cristina Vidulescu; Irina Stoian; Daciana S Marta; S Tanaseanu; Elena Moldoveanu Journal: J Cell Mol Med Date: 2002 Oct-Dec Impact factor: 5.310
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Steven R Coughlin; Lynn Mawdsley; Julie A Mugarza; Peter M A Calverley; John P H Wilding Journal: Eur Heart J Date: 2004-05 Impact factor: 29.983